Jove
Visualize
Contact Us

Related Experiment Videos

Fabry disease.

Mark Levin1

  • 1Department of Hematology and Oncology, University Hospital of New Jersey Medical School, Newark, New Jersey 07101, USA. mlevinmd@aol.com

Drugs of Today (Barcelona, Spain : 1998)
|March 3, 2006
PubMed
Summary
This summary is machine-generated.

Fabry disease is an inherited enzyme deficiency affecting galactosidase A, leading to varied symptoms. Enzyme replacement therapy shows promise in managing and preventing disease complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fentanyl Initiation Rate Following the Requirement for Specialist Approval.

Journal of general internal medicine·2024
Same author

Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome.

Nature communications·2024
Same author

C-C Coupling through Nitrogen Deletion: Application to Library Synthesis.

Chemistry (Weinheim an der Bergstrasse, Germany)·2023
Same author

C-C Coupling through Nitrogen Deletion: Application to Library Synthesis.

Chemistry (Weinheim an der Bergstrasse, Germany)·2022
Same author

Baz1b Dosage Influences Cardiovascular Function, Predisposing to Dilated Cardiomyopathy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2022
Same author

Severity modeling of propionic acidemia using clinical and laboratory biomarkers.

Genetics in medicine : official journal of the American College of Medical Genetics·2021
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Genetics and rare diseases
  • Metabolic disorders
  • Enzyme replacement therapy

Background:

  • Fabry disease is a genetic lysosomal storage disorder caused by deficient alpha-galactosidase A activity.
  • This deficiency leads to the accumulation of globotriaosylceramide, impacting multiple organ systems.
  • Clinical manifestations are diverse, including neurological, cardiac, and renal complications.

Purpose of the Study:

  • To review the effectiveness of enzyme replacement therapy (ERT) in managing Fabry disease.
  • To highlight the potential of ERT in preventing disease progression and associated complications.

Main Methods:

  • Review of preclinical and clinical studies on enzyme infusion for Fabry disease.
  • Analysis of data on the efficacy of ERT in controlling disease phenotypes.

Related Experiment Videos

Main Results:

  • Preclinical studies indicate ERT's ability to reduce substrate accumulation.
  • Clinical trials demonstrate that enzyme infusion can effectively manage cardiac and renal manifestations.
  • ERT has shown potential in preventing the onset or worsening of neurological symptoms.

Conclusions:

  • Enzyme infusion is an effective therapeutic strategy for Fabry disease.
  • ERT plays a crucial role in controlling and preventing the diverse clinical manifestations of Fabry disease.
  • Further research should focus on long-term outcomes and personalized treatment approaches.